Stevens Capital Management LP Has $324,000 Stake in Insulet Co. (NASDAQ:PODD)

Stevens Capital Management LP lessened its holdings in Insulet Co. (NASDAQ:PODD) by 79.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,494 shares of the medical instruments supplier’s stock after selling 5,890 shares during the period. Stevens Capital Management LP’s holdings in Insulet were worth $324,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Syon Capital LLC bought a new position in shares of Insulet during the 4th quarter worth approximately $288,000. Atria Wealth Solutions Inc. purchased a new position in Insulet in the fourth quarter worth $288,000. GAMMA Investing LLC purchased a new stake in Insulet during the fourth quarter valued at about $55,000. Linden Thomas Advisory Services LLC raised its stake in shares of Insulet by 1.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock valued at $1,262,000 after acquiring an additional 73 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Insulet by 57.7% during the fourth quarter. Jennison Associates LLC now owns 207,519 shares of the medical instruments supplier’s stock valued at $45,027,000 after acquiring an additional 75,954 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.90% of the company’s stock.

Insulet Stock Up 1.2 %

Shares of PODD stock traded up $2.02 during trading hours on Friday, hitting $166.19. 636,152 shares of the company were exchanged, compared to its average volume of 862,355. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The business’s 50-day simple moving average is $172.00 and its two-hundred day simple moving average is $179.25. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The stock has a market capitalization of $11.64 billion, a price-to-earnings ratio of 57.07, a P/E/G ratio of 3.01 and a beta of 0.98.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. During the same quarter in the previous year, the business earned $0.55 EPS. Insulet’s quarterly revenue was up 37.9% compared to the same quarter last year. Sell-side analysts predict that Insulet Co. will post 3.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Barclays dropped their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research note on Monday, February 26th. Stifel Nicolaus increased their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Finally, Piper Sandler cut their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.